ARTICLE | Company News
Peregrine, Memorial Sloan Kettering deal
June 15, 2015 7:00 AM UTC
Peregrine and Memorial Sloan Kettering partnered to identify treatment combinations based on Peregrine’s phosphatidylserine (PS)-targeting antibody platform to treat cancer. The cancer center will perform research to explore the combination of PS-targeting agents, including Peregrine’s lead compound bavituximab, with other checkpoint inhibitors or immune-stimulating agents. The partners declined to disclose financial terms or other details. ...